Lipid-encapsulated mRNA encoding an extended serum half-life interleukin-22 ameliorates metabolic disease in mice.

Unlike mice treated with MSA, those that received MSA-IL-22 did not present with liver hypertrophy; however, this difference did not reach statistical significance ( Figure 3 C).

also in 111,027 other papers